Global Oligonucleotide Synthesis Market, By Product (Oligonucleotide, Reagents, and Equipment), Type (Custom Oligos and Predesigned Oligos), Application (Therapeutic Applications, Diagnostics, Research, and Others), End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, and Others) – Industry Trends and Forecast to 2031.
Oligonucleotide Synthesis Market Analysis and Size
The oligonucleotide synthesis market continues to witness significant advancements, driving innovation in biotechnology and pharmaceutical research. Cutting-edge technologies enhance synthesis efficiency, offering benefits such as rapid production, cost-effectiveness, and high accuracy. These advancements propel drug discovery, diagnostics, and personalized medicine, revolutionizing molecular biology applications worldwide.
For instance, in November 2023, Twist Bioscience launched Express Genes, offering rapid gene synthesis within 5 to 7 business days. Operated from their Wilsonville, Oregon facility, this service accelerates gene production for various synthetic biology and genomics applications.
Data Bridge Market Research analyses that the global oligonucleotide synthesis market size was valued at USD 8.61 billion in 2023, is projected to reach USD 21.01 billion by 2031, with a CAGR of 11.8% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Oligonucleotide, Reagents, and Equipment), Type (Custom Oligos and Predesigned Oligos), Application (Therapeutic Applications, Diagnostics, Research, and Others), End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
Agilent Technologies, Inc. (U.S.), Atdbio Ltd. (U.K.), LGC Limited (U.K.), Bio-Synthesis Inc. (U.S.), Eurofins Genomics (India), Kaneka Eurogentec S.A.(Belgium), General Electric (U.S.), Genscript (U.S.), Ajinomoto Co., Inc. (Japan), Genedesign, Inc. (Tokyo), Danaher (U.S.), and Merck KgaA (Germany)
|
|
Market Opportunities
|
|
Market Definition
Oligonucleotide synthesis is the chemical process of creating short sequences of nucleotides, typically DNA or RNA, in the laboratory. It involves assembling nucleotides using chemical reactions, often on a solid support. This method is crucial in molecular biology, genetic engineering, and medical research for DNA sequencing and gene synthesis applications.
Oligonucleotide Synthesis Market Dynamics
Drivers
- Growing Demand in Therapeutics
The rising demand for oligonucleotide synthesis services is fueled by their pivotal role in therapeutic applications such as antisense therapy, siRNA-based treatments, and aptamer-based drugs. With an expanding pipeline of oligonucleotide drugs targeting diseases such as cancer, genetic disorders, and infectious diseases, the need for synthesis services is growing to meet drug development demands.
For instance, In February 2023, Fluor Corp. partnered with Agilent Technologies, Inc. to upgrade its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. Fluor will provide engineering and procurement support for the project, valued at USD 725 million.
- Rising Research in Molecular Biology and Synthetic Biology
Oligonucleotides are pivotal in molecular and synthetic biology, facilitating gene expression analysis, cloning, and protein synthesis. The demand for oligonucleotide synthesis services surges as research delves deeper into cellular mechanisms and engineers’ biological systems. This trend underscores their indispensable role in advancing biological sciences and creating novel biomolecules.
Opportunities
- Advancements in Genomics and Personalized Medicine
The surge in genomics research and personalized medicine propels the demand for oligonucleotides. Crucial in DNA sequencing, gene editing such as CRISPR/Cas9, and diagnostics, oligonucleotides are indispensable tools. As these domains progress, the necessity for top-tier, tailored oligonucleotides surges, underscoring their pivotal role in advancing medical and genomic sciences.
For instance, in August 2023, UC San Diego initiated a Gene Therapy Initiative to pioneer novel treatments for rare diseases. This endeavor was enabled by a generous USD 5 million contribution from the Nancy and Geoffrey Stack Foundation.
- Regulatory Support and Approval of Oligonucleotide Therapeutics
Growing regulatory backing from the FDA and EMA for oligonucleotide therapeutics enhances trust in their safety and effectiveness, fostering confidence among stakeholders. Recent approvals of oligonucleotide drugs have spurred greater investment and adoption in the pharmaceutical sector, driving market growth and advancing the development of novel therapeutic solutions.
Restraints/Challenges
- High Cost of Oligonucleotide Synthesis
Oligonucleotide synthesis is hindered by high costs due to expensive reagents and equipment. Limited budgets present a significant barrier, particularly for smaller research labs and companies, hindering their ability to invest in advanced technologies. Affordability issues restrict access to this technology, impacting innovation and research advancement in various fields reliant on oligonucleotide synthesis applications.
- Supply Chain Vulnerabilities
The oligonucleotide synthesis market faces supply chain vulnerabilities due to reliance on specific raw materials and reagents. Disruptions in the supply chain can impact product availability and costs, posing challenges for manufacturers and potentially affecting research and diagnostic activities reliant on oligonucleotide products.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In October 2023, IDT unveiled a new therapeutic manufacturing facility to meet surging demand in genomic medicine. Equipped for oligonucleotide production, it addresses expanding needs in genomics and personalized medicine
- In September 2023, Danaher Corp. launched xGen NGS products tailored for the Ultima Genomics UG 100TM platform, encompassing adapters, primers, and universal blockers. Enhancing DNA, RNA, & methylation sequencing workflows, it integrates IDT's hybridization capture chemistry
- In July 2023, Analytix launched two instruments, wavePREP for oligonucleotide synthesis and Xelsius for multireaction synthesis, catering to organic synthesis requirements
- In May 2023, GenScript expanded its Zhenjiang, Jiangsu, China facility, offering rapid, high-purity oligonucleotide and peptide synthesis services for research & development and preclinical applications
Oligonucleotide Synthesis Market Scope
The market is segmented on the basis of product, type, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Oligonucleotide
- DNA
- Column-based
- Array-based
- RNA
- Technology
- Column-based
- Array-based
- Type
- Short RNA Oligos (<65 nt)
- Long RNA Oligos (>65 nt)
- CRISPR (sgRNA)
- Technology
- DNA
- Reagents
- Equipment
Type
- Custom Oligos
- Predesigned Oligos
Application
- Therapeutic Applications
- Diagnostics
- Research
- Others
End User
- Academic Research Institutes
- Pharmaceutical and Biotechnology Companies,
- Diagnostic Laboratories
- Others
Oligonucleotide Synthesis Market Regional Analysis/Insights
The market is analyzed and market size insights and trends are provided by country, product, type, application, and end user as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
Asia-Pacific is expected to witness significant growth in the market, driven by increased government initiatives, growing research activities, and untapped markets. With a large population pool and rising demand for quality healthcare, the region presents vast opportunities for innovation and expansion in oligonucleotide synthesis technologies and services.
North America is expected to dominate the oligonucleotide synthesis market due to its robust healthcare infrastructure, the significant presence of key industry players, escalating viral disease instances, and a surge in research endeavors. These factors propel the region's leadership in advancing oligonucleotide synthesis technologies and applications.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Oligonucleotide Synthesis Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the oligonucleotide synthesis market are:
- Agilent Technologies, Inc. (U.S.)
- Atdbio Ltd. (U.K.)
- LGC Limited (U.K.)
- Bio-Synthesis Inc. (U.S.)
- Eurofins Genomics (India)
- Kaneka Eurogentec S.A. (Belgium)
- General Electric (U.S.)
- Genscript (U.S.)
- Ajinomoto Co., Inc. (Japan)
- Genedesign, Inc. (Tokyo)
- Danaher (U.S.)
- Merck KgaA (Germany)
SKU-